SPOTLIGHT -
EP. 1: Molecular Pathogenesis of Multiple Myeloma
EP. 2: Defining High-Risk Multiple Myeloma
EP. 3: Managing Smoldering Myeloma
EP. 4: Treatment Regimens for Transplant Ineligible Myeloma
EP. 5: Treating Multiple Myeloma in Elderly Populations
EP. 6: Transplant-Eligible Patients in Multiple Myeloma
EP. 7: Consolidation and Maintenance Therapy in Multiple Myeloma
EP. 8: Managing Relapsed Disease in Multiple Myeloma
EP. 9: Significance of the ENDEAVOR Trial in Multiple Myeloma
EP. 10: Elotuzumab and Ixazomib in Multiple Myeloma
EP. 11: Applying New Multiple Myeloma Agents to Practice
EP. 12: Using Pomalidomide in Multiple Myeloma
EP. 13: FDA Labels of New Multiple Myeloma Agents
EP. 14: Potential Role of Daratumumab in Multiple Myeloma
EP. 15: Latest Advances in Multiple Myeloma Treatment
EP. 16: Continuing Anti PD-1 Therapy Beyond RECIST Progression
Dr Berkenstock on ADC-Related Ocular Toxicities in Cervical and Ovarian Cancers
Dr Matalonis on the Management of Mirvetuximab Soravtansine-Related Toxicities in FRα+ Ovarian Cancer
Updated EMPOWER-Lung 3 Data Support Frontline Cemiplimab Plus Chemo in Advanced NSCLC
Neoadjuvant Nivolumab Plus Chemotherapy Retains EFS Advantage in Resectable NSCLC
